Real‐World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic Mutations
Adjuvant systemic therapy improved RFS in our cohort. We found that BRAF V600 mutation was associated with a worse RFS for adjuvant anti-PD1 monotherapy. The effect of BRAF mutation on the response to anti-PD1 therefore may be considered when choosing between adjuvant anti-PD1 and BRAFi/MEKi for patients with BRAF V600 mutant melanoma.
Authors
- Benjamin Park (ORCID: https://orcid.org/0000-0001-7119-5632)
- Ryan J. Sullivan (ORCID: https://orcid.org/0000-0001-5344-6645)
- Genevieve Marie Boland (ORCID: https://orcid.org/0000-0002-7522-6173)
- Seungyeon Jung (ORCID: https://orcid.org/0000-0001-8407-9411)
- Alexander Maxwell Menzies (ORCID: https://orcid.org/0000-0001-5183-7562)
- Keith T. Flaherty (ORCID: https://orcid.org/0000-0002-3402-0478)
- Tatyana Sharova (ORCID: https://orcid.org/0000-0003-2123-3906)
- Douglas Buckner Johnson (ORCID: https://orcid.org/0000-0002-6390-773X)
- Derek N Effiom (ORCID: https://orcid.org/0000-0001-7534-9029)
- Sonia Cohen (ORCID: https://orcid.org/0000-0003-0172-5620)
- Xue Bai (ORCID: https://orcid.org/0000-0002-5203-4080)
- Tyler Aprati
- Georgina Venetia Long (ORCID: https://orcid.org/0000-0001-8894-3545)
- Aleigha Lawless (ORCID: https://orcid.org/0009-0009-3861-3164)
- Anastasios Karneris
- David Liu (ORCID: https://orcid.org/0000-0003-0346-5033)
- Rebecca Johnson
Institutions
- Broad Institute (US)
- The University of Sydney (AU)
- Harvard University (US)
- Royal North Shore Hospital (AU)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
- Melanoma Institute Australia (AU)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/cam4.71410
- Citations
- 1
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.81